A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

Alves C, Batel-Marques F, Macedo AF

Diabetes research and clinical practice23 Sept 2012Cited by 142 (Europe PMC)

PMID23010561DOI10.1016/j.diabres.2012.09.008PepBankPUB-23010561

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, liraglutide was not associated with an increased risk of acute pancreatitis in a pooled analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide was not linked to a higher risk of acute pancreatitis.
Peptide
Liraglutide
Outcome
No significant changeAcute pancreatitis risk
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
Dose not stated
Measurements
Pooled odds ratio
0.97
acute pancreatitis, liraglutide
Source sentences
Summary
nor liraglutide (OR 0.97 [95% CI 0.21-4.39], I(2) = 0%) were associated with an increased risk of AP, independent of baseline comparator.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, EMBASE, Cochrane Library and clinicaltrials.gov were searched in order to identify longitudinal studies evaluating exenatide or liraglutide use and reporting data on AP or cancer.
Report a problemFND-2301056101
02HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, the pooled odds ratio for any cancer with liraglutide did not show a significant increase in risk.
In plain wordsIn adults with type 2 diabetes, liraglutide was not linked to a clear rise in the risk of cancer.
Peptide
Liraglutide
Outcome
No significant changeCancer risk
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Measurements
Pooled odds ratio
1.35
any cancer, liraglutide
Source sentences
Summary
for liraglutide was 1.35 (95% CI 0.70, 2.59, I(2) = 0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, EMBASE, Cochrane Library and clinicaltrials.gov were searched in order to identify longitudinal studies evaluating exenatide or liraglutide use and reporting data on AP or cancer.
Report a problemFND-2301056102
03HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, liraglutide was not associated with an increased risk of thyroid cancer in a pooled analysis.
In plain wordsIn adults with type 2 diabetes, liraglutide was not linked to a higher risk of thyroid cancer.
Peptide
Liraglutide
Outcome
No significant changeThyroid cancer risk
Study
n: not reported in source
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Measurements
Pooled odds ratio
1.54
thyroid cancer, liraglutide
Source sentences
Summary
Liraglutide was not associated with an increased risk for thyroid cancer (OR 1.54 [95% CI 0.40-6.02], I(2) = 0%).
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, EMBASE, Cochrane Library and clinicaltrials.gov were searched in order to identify longitudinal studies evaluating exenatide or liraglutide use and reporting data on AP or cancer.
Report a problemFND-2301056103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials11

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

11 trials · 10 completed · 1 stopped early · 8 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817